Overview
TENX market data
Price History
TENX price chart
Valuation & Profitability
- P/E (TTM)
- — Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
- Forward P/E
- — P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
- EPS (TTM)
- -$1.34 Diluted earnings per share over the trailing twelve months.
- Beta
- 0.94 Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
- Dividend Yield
- — Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
- Profit Margin
- — Net income divided by revenue. Comparable within a sector, less so across sectors.
- 52w range
- $5.78 – $19.40 Lowest and highest closing prices over the past 52 weeks.
- Analyst Target
- — Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.
Display-only. Refreshed once per symbol per 24 hours · source Twelve Data /statistics · market cap $390.5 · P/B 0.78 · P/S 7,919.88.
Company News
Tenax Therapeutics Q2 EPS $(0.35) Beats $(0.37) EstimateBenzinga · Jul 31, 2026, 11:29 AM
8-K filing — TENAX THERAPEUTICS, INC. (TENX)SEC EDGAR · Jul 31, 2026, 11:23 AM
Canaccord Genuity Initiates Coverage On Tenax Therapeutics with Buy Rating, Announces Price Target of $35Benzinga · Jul 28, 2026, 1:14 PM
Evercore ISI Group Initiates Coverage On Tenax Therapeutics with Outperform Rating, Announces Price Target of $39Benzinga · Jul 22, 2026, 2:59 PM
Rivian Automotive, Tenax Therapeutics, Robinhood And Other Big Stocks Moving Higher On ThursdayBenzinga · Jul 2, 2026, 2:30 PM
Tenax Therapeutics To Present Results From Phase 3 LEVEL Clinical Trial In Late-Breaking Clinical Science Session At ESC Congress 2026Benzinga · Jul 2, 2026, 11:10 AM
Cantor Fitzgerald Reiterates Overweight on Tenax Therapeutics, Maintains $35 Price TargetBenzinga · Jun 24, 2026, 2:10 PM
Guggenheim Maintains Buy on Tenax Therapeutics, Raises Price Target to $40Benzinga · Jun 22, 2026, 1:40 PM
Chardan Capital Initiates Coverage On Tenax Therapeutics with Buy Rating, Announces Price Target of $27Benzinga · Jun 22, 2026, 12:50 PM
Piper Sandler Maintains Overweight on Tenax Therapeutics, Raises Price Target to $50Benzinga · Jun 12, 2026, 4:40 PM